THOMAS J. APPIO - Corporate Board Profile

Bausch Health Companies Inc.

Filing Date	Source Excerpt
2022-05-02	Mr. Appio will serve as CEO and a director of the Company effective upon the completion of the B+L IPO. He has served as the Companys President & Co-Head Bausch + Lomb/International since August 2018, and was previously Executive Vice President, Company Group Chairman, International from August 2016 until July 2018. ... 2021 Meeting Attendance: Not applicable.
2023-04-06	Mr. Appio has been the Chief Executive Officer of the Company since May 2022. He previously served as the Company’s President & Co-Head Bausch + Lomb/ International and Executive Vice President, Company Group Chairman, International. Prior to joining Bausch Health in 2013, Mr. Appio served in several positions with Bausch + Lomb, including as Vice President, North Asia/Japan and as Managing Director, Greater China and Japan. Prior to joining Bausch + Lomb, Mr. Appio served 23 years with Schering-Plough in a wide range of leadership and operations responsibilities. Mr. Appio holds a Bachelor of Science in Accounting from Arizona State University, W.P. Carey School of Business. Stock Ownership: 194,862 Common Shares — $1,480,051 • 695,999 RSUs (comprised of 695,999 unvested RSUs — $5,289,592) • 482,201 Stock Options • Total Equity Value at Risk: $1,480,051 based on the value of the Common Shares beneficially owned by Mr. Appio (but excluding all options and unvested RSUs). Mr. Appio is subject to share ownership guidelines under the terms of his employment agreement with the Company, as further described in the section titled “Compensation Discussion and Analysis — Other Compensation Governance Practices – Share Ownership Guidelines” on page 56. 2022 Meeting Attendance: • Board: 9/9 Qualifications: The Board has determined that Mr. Appio’s extensive management experience and demonstrated leadership with the Company is a valuable contribution to the Board.
2024-04-04	Mr. Appio was appointed to the Board and has been the Chief Executive Officer of the Company since May 2022. He previously served as the Company’s President & Co-Head Bausch + Lomb/International, the Company’s eye-health business, from August 2018 until October 2021, and also served as Executive Vice President, Company Group Chairman, International from August 2016 until July 2018. Prior to its acquisition by Bausch Health in 2013, Mr. Appio served in several positions with Bausch + Lomb Corporation (“Bausch + Lomb” or “B+L”), including as Vice President, North Asia/Japan and as Managing Director, Greater China and Japan. Prior to joining Bausch + Lomb, Mr. Appio served 23 years with Schering-Plough in a wide range of leadership and operations responsibilities. Mr. Appio holds a Bachelor of Science in Accounting from Arizona State University, W.P. Carey School of Business. Stock Ownership: 420,274 Common Shares — $3,866,521; 949,082 Restricted Share Units (“RSUs”) (comprised of 949,082 unvested RSUs —$8,731,554); 852,455 Stock Options (“SOPs”) (comprised of 664,011 vested SOPs — $6,108,901, and 188,444 unvested SOPs— $1,733,685). Total Equity Value at Risk: $3,866,521 based on the value of the Common Shares beneficially owned by Mr. Appio (but excluding all SOPs and unvested RSUs). Mr. Appio is subject to share ownership guidelines under the terms of his employment agreement with the Company, as further described in the section titled “Compensation Discussion and Analysis – Other Compensation Governance Practices – Share Ownership Guidelines” on page 52. 2023 Meeting Attendance: Board: 8/8; Science & Technology Committee: 3/3. The Board has determined that Mr. Appio’s extensive management experience and demonstrated leadership with the Company is a valuable contribution to the Board.
2025-04-02	Mr. Appio was appointed to the Board and has been the Chief Executive Officer of the Company since May 2022. ... The Board has determined that Mr. Appio is not an independent director and will not be eligible to serve on the Audit and Risk Committee, the Talent and Compensation Committee, or the Nominating and Corporate Governance Committee. ... 2024 Summary Compensation Table shows total compensation of $16,239,133.